Evolution of the influenza A virus genome during development of oseltamivir resistance in vitro
Caffrey, Daniel R.
Zeldovich, Konstantin B.
Gallagher, Glen R.
Porter, Alyssa J.
Kurt-Jones, Evelyn A.
Bolon, Daniel N.
Jensen, Jeffrey D.
Schiffer, Celia A.
Kowalik, Timothy F.
Finberg, Robert W.
Wang, Jennifer P.
UMass Chan AffiliationsDepartment of Biochemistry and Molecular Pharmacology
Program in Bioinformatics and Integrative Biology
Department of Medicine, Division of Infectious Diseases and Immunology
Department of Microbiology and Physiological Systems
Document TypeJournal Article
Drug Resistance, Viral
High-Throughput Screening Assays
In Vitro Techniques
Influenza A Virus, H1N1 Subtype
Inhibitory Concentration 50
Viral Plaque Assay
Biochemistry, Biophysics, and Structural Biology
Cellular and Molecular Physiology
MetadataShow full item record
AbstractInfluenza A virus (IAV) is a major cause of morbidity and mortality throughout the world. Current antiviral therapies include oseltamivir, a neuraminidase inhibitor that prevents the release of nascent viral particles from infected cells. However, the IAV genome can evolve rapidly, and oseltamivir resistance mutations have been detected in numerous clinical samples. Using an in vitro evolution platform and whole-genome population sequencing, we investigated the population genomics of IAV during the development of oseltamivir resistance. Strain A/Brisbane/59/2007 (H1N1) was grown in Madin-Darby canine kidney cells with or without escalating concentrations of oseltamivir over serial passages. Following drug treatment, the H274Y resistance mutation fixed reproducibly within the population. The presence of the H274Y mutation in the viral population, at either a low or a high frequency, led to measurable changes in the neuraminidase inhibition assay. Surprisingly, fixation of the resistance mutation was not accompanied by alterations of viral population diversity or differentiation, and oseltamivir did not alter the selective environment. While the neighboring K248E mutation was also a target of positive selection prior to H274Y fixation, H274Y was the primary beneficial mutation in the population. In addition, once evolved, the H274Y mutation persisted after the withdrawal of the drug, even when not fixed in viral populations. We conclude that only selection of H274Y is required for oseltamivir resistance and that H274Y is not deleterious in the absence of the drug. These collective results could offer an explanation for the recent reproducible rise in oseltamivir resistance in seasonal H1N1 IAV strains in humans.
SourceJ Virol. 2014 Jan;88(1):272-81. doi: 10.1128/JVI.01067-13. Epub 2013 Oct 23. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/26069
Related ResourcesLink to Article in PubMed
Copyright © 2014, American Society for Microbiology. All Rights Reserved. Publisher PDF posted as allowed by the publisher's author rights policy at http://journals.asm.org/site/misc/ASM_Author_Statement.xhtml.